Therapeutic Antibody Start-Ups
This article was originally published in Start Up
After more than a decade of anticipation, pharmas have now clearly recognized the value of antibodies as therapeutics. And biotechs can offer discovery tools and development expertise.
You may also be interested in...
None of the marketed humanized monoclonal antibodies and very few of those in development target nervous system disorders. Rinat Neuroscience Corp. hopes to turn heads by pioneering highly targeted antibody therapies for pain, neuropathy and other neural disorders.
With an engineered cell line, Acceptys can capture, screen and produce naturally occurring human antibodies ex vivo.
A handful of companies control the intellectual property for and offer access to human antibody discovery and engineering capabilities. KaloBios thinks it will be one of them, having built a platform of proprietary in vitro technologies for creating and optimizing human antibodies. To fully leverage the value of its technology platform, the start-up is becoming vertically integrated, via a merger with Celscia Therapeutics, which will give it the capability to not only discover and engineer clinically relevant antibodies, but also to develop them and bring them through to the clinic quickly.